Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ unit -- Taro Pharmaceutical Industries is recalling over 17,000 units of an antifungal medication in the US due to manufacturing issues. The company is recalling the affected lot due to Failed Impurity/Degradation specifications. The company initiated the Class II nationwide recall on December 9 this year. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharmaceutical Industries completed the merger of Taro Pharmaceutical Industries with itself in a deal valued at $347.73 million last year.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.